Contact Us
Drug Search Results
More Filters [+]

Sonolisib

Alternative Names: sonolisib, px-866
Latest Update: 2023-08-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PI3K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sonolisib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Melanoma|Glioblastoma|Non-Small-Cell Lung Cancer|Colorectal Cancer|Squamous Cell Carcinoma|Head and Neck Cancer|Prostate Cancer

Phase 1: Healthy Volunteers|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
I205

P2

Completed

Prostate Cancer

2015-01-13

PX-866-007

P2

Terminated

Melanoma

2014-12-01

I204

P2

Completed

Glioblastoma

2014-10-29

PX-866-002

P2

Completed

Non-Small-Cell Lung Cancer|Head and Neck Cancer|Squamous Cell Carcinoma

2013-12-01

Recent News Events

Date

Type

Title

07/01/2023

PubMed

 Suppression of Autophagy Can Augment PIK3 Inhibitor Induced Apoptosis in T Lymphoblastic Leukemia Cell Lines.

09/15/2022

PubMed

 Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis.

08/19/2022

PubMed

 Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions